Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients
Purpose We investigated the prevalence of BRCA1/2 small mutations and large genomic rearrangements in high risk breast cancer patients who attended a genetic counseling clinic. Methods In total 478 patients were assessed for BRCA1/2 mutations by direct sequencing, of whom, 306 were identified as non...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2017-05, Vol.163 (1), p.139-150 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
We investigated the prevalence of
BRCA1/2
small mutations and large genomic rearrangements in high risk breast cancer patients who attended a genetic counseling clinic.
Methods
In total 478 patients were assessed for
BRCA1/2
mutations by direct sequencing, of whom, 306 were identified as non-carriers of
BRCA1/2
mutation and assessed for large rearrangement mutations by multiplex ligation-dependent probe amplification. Family history and clinicopathological characteristics of patients were evaluated.
Results
Sixty-three mutation carriers (13.2%) were identified with
BRCA1
mutations (6.3%) and
BRCA2
mutations (6.9%), respectively. Mutation frequency was affected by familial and personal factors. Breast cancer patients with family history of breast and ovarian cancer showed the highest prevalence of
BRCA1/2
mutations (67%), and triple-negative breast cancer (TNBC) patients showed high
BRCA1
mutation prevalence (25%). The three probands of
BRCA1
deletion (1%) represented both familial risk and personal or clinicopathological risk factors as two with TNBC and one with bilateral ovarian cancer.
Discussion
This is the largest study assessing large genomic rearrangement prevalence in Korea and
BRCA1
deletion frequency was low as 1% in patients without
BRCA1/2
small mutations. For clinical utility of large genomic rearrangement testing needs further study. |
---|---|
ISSN: | 0167-6806 1573-7217 |
DOI: | 10.1007/s10549-017-4142-7 |